March 01, 2019

Tmunity Announces Participation at Four Upcoming Investor Conferences

PHILADELPHIA, PA, March 1, 2019 – Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at four investor conferences in March 2019.

 

  • Cowen and Company 39th Annual Health Care Conference

Monday, March 11, 2019

Podium presentation at 12:00 p.m. ET

Boston, MA

 

  • Barclays Global Health Care Conference

Tuesday, March 12, 2019

Miami Beach, FL

 

  • Oppenheimer’s 29th Annual Health Care Conference

Tuesday, March 19, 2019

New York, NY

 

  • William Blair 9th Annual Cancer Immunotherapy Conference

Wednesday, March 20, 2019

Podium presentation at 9:25 a.m. ET

New York, NY

About Tmunity Therapeutics

Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer with two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.

 

# # #

Tmunity Contacts:

Investors:

Graeme Bell

Chief Financial Officer

ir@tmunity.com

215-966-1600    

 

Media:

Mike Beyer, Sam Brown Inc.

mikebeyer@sambrown.com

312-961-2502

Legal  |  Privacy  |  Cookies

Tmunity Therapeutics Inc.
3020 Market Street, Suite 535
Philadelphia, PA 19104

+1 215 966 1600

© 2018 Tmunity Therapeutics. All rights reserved.